Dexcom anticipates $1.26B in Q4 revenue 

SAN DIEGO – Dexcom reported preliminary, unaudited total revenue of $1.260 billion for the fourth quarter of 2025, an increase of 13% over the fourth quarter of 2024. U.S. revenue is expected to be approximately $892 million, representing growth of 11% over the fourth quarter of 2024. International revenue is expected to be approximately $368 million, an increase of 18% over the fourth quarter of 2024. For fiscal 2025, total preliminary, unaudited revenue is approximately $4.662 billion, an increase of 16% over 2024. “We are pleased to finish 2025 on a strong note with revenue exceeding the high end of our guidance and the initial launch of our latest sensor technology with the G7 15 Day system,” said Jake Leach, Dexcom’s president and CEO. “With clinical momentum building across the CGM category, we look forward to extending our growth runway through continued innovation and evidence generation in 2026.” 

2025 Highlights 

On Jan. 1, Jake Leach officially assumed the role of president and CEO at DexCom, taking over from Kevin Sayer. 

“I’ve had the honor of playing a role in shaping Dexcom’s industry-defining innovation since joining the company more than 20 years ago,” he said. “From building the technology as an engineer in my early days, to advancing global scale to meet our long-term growth demand as COO, it’s an honor to step into the role of CEO during such a pivotal moment for the business—and a growing global metabolic health crisis. I look forward to further advancing Dexcom’s long legacy of empowering people to take control of health.” 

The company launched the G7 15 Day CGM System on Dec. 1.  

2026 Outlook 

For 2026, Dexcom currently anticipates total revenue of $5.16 billion to $5.25 billion, representing expected growth of approximately 11% to 13% over 2025. This outlook considers sensor volume growth driven by increasing CGM awareness for people with diabetes, the continued rollout of Stelo, further international expansion, and overall market dynamics.